| Trial ID: | L0201 |
| Source ID: | NCT00626249
|
| Associated Drug: |
Technosphere Inhalation Powder
|
| Title: |
Single Dose, Single Administration Study of Technosphere Inhalation Powder in Diabetic Subjects With Mild or Moderate Kidney Disease Compared to Diabetic Subjects With Normal Kidney Function
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Mild Nephropathy|Moderate Nephropathy|Diabetes Mellitus
|
| Interventions: |
DRUG: Technosphere Inhalation Powder
|
| Outcome Measures: |
Primary: Differences in exposure to fumaryl diketopiperazine (FDKP), 14 days | Secondary: Additional safety parameters, 14 days
|
| Sponsor/Collaborators: |
Sponsor: Mannkind Corporation
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
36
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2007-08
|
| Completion Date: |
2008-10
|
| Results First Posted: |
|
| Last Update Posted: |
2013-12-17
|
| Locations: |
Davita Clinical Research, Minneapolis, Minnesota, 55404, United States|Qualia Clinical Research, Omaha, Nebraska, 68154, United States|Diabetes & Glandular Disease Research Assoc PA, San Antonio, Texas, 78229, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00626249
|
